http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2009509496-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2469-20 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-195 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-56911 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-195 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-106 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-569 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53 |
| filingDate | 2006-04-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2009-03-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2009509496-A |
| titleOfInvention | Immunological protein of Lawsonia intracellularis |
| abstract | The present invention relates to an immunogen of a vaccine or immunogenic composition effective to reduce the severity of clinical symptoms associated with Lawsonia intracellularis infection or to provide protective immunity to animals susceptible to the infection. Nucleotide sequences and amino acid sequences useful as sex parts are provided. Preferred amino acid sequences are: 1) a sequence comprising a sequence selected from the group consisting of SEQ ID NO: 1-455, SEQ ID NO: 466 or SEQ ID NO: 456, SEQ ID NO: 457 or the polypeptide encoded by SEQ ID NO: 466; Peptide; 2) at least 85% sequence homology with the polypeptide of 1), more preferably at least about 90% sequence homology, even more preferably at least about 95% sequence homology, even more preferably about 97% Any polypeptide having a sequence homology, even more preferably at least about 98% sequence homology, and even more preferably at least about 99% sequence homology; 3) a polypeptide of 1) and / or 2) 4) included in the sequence of the amino acid sequence encoded by SEQ ID NO: 1-455, SEQ ID NO: 456 or SEQ ID NO: 457 or SEQ ID NO: 466 At least 300, 290, 280, 270, 260, 250, 240, 230, 220, 210, 200, 190, 180, 170, 160, 150 140, 130, 120, 110, 100, 90, 80, 70, 60, 50, 45, 40, 35, 30, 25, 20, 18, 18 3) an immunogenic portion comprising 1, 15, 13, 10 or most preferably at least 9 consecutive amino acids; and / or 5) the sequence of SEQ ID NO: 1-455 or SEQ ID NO: 466 Selected from the group consisting of a polypeptide encoded by a DNA encoding a peptide comprising. Accordingly, the nucleotide sequence encoding the protein or the protein itself is included in the vaccine composition together with a veterinary acceptable carrier and administered to an animal in need thereof. |
| priorityDate | 2005-04-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 272.